1. The similarity in molecular structure between the histamine H2-agonist dimaprit (3-dimethylamino-propyl-isothiourea) and the endogenous nitric oxide synthase (NOS) substrate L-arginine prompted us to study the effect of dimaprit and some dimaprit analogues on NOS activity. Dimaprit and some of its analogues were tested in an in vitro assay which measures the conversion of [3H]-Larginine to [3H]-L-citrulline. Dimaprit inhibits rat brain NOS (nNOS) concentration dependently with an IC50 of 49+/-14 microM. 2. Removal of one or both of the methyl groups from the non-isothiourea nitrogen of dimaprit improved nNOS inhibitory properties. Aminopropylisothiourea is the most potent compound (IC50 = 4.1+/-0.9 microM) of the series followed by methylaminopropylisothiourea (IC50 = 7.6 +/-microM). 3. The observed effect of aminopropylisothiourea and methylaminopropyl-isothiourea are probably not due to the compounds themselves but to the corresponding mercaptoalkylguanidines, rearrangement pr...
Introduction
The nitric oxide radical (NO) is involved in various biological processes including endothelium dependent relaxation of blood vessels and lung tissue as well as cell-mediated immunoresponses. NO is also a neurotransmittor associated with learning and memory processes (Schmitt & Walter, 1994) . Nitric oxide is synthesized by the nitric oxide synthase enzymes (NOS). These enzymes catalyse the 5 electron oxidation of Larginine and produce L-citrulline and NO. Three dierent subtypes of NOS are distinguished. Two constitutive calciumdependent forms, one discovered in endothelium cells called eNOS, the other present in neuronal cells, known as nNOS (or bNOS from brain). The third subtype is an inducible calciumindependent enzyme, especially present in macrophages, iNOS (Nathan & Xie, 1994) . All three subtypes of NOS require heam, calmodulin,¯avin adenine dinucleotide (FAD),¯avin mononucleotide (FMN) and tetrahydrobiopterin (BH 4 ) as cofactors and NADPH and molecular oxygen as cosubstrates to oxidize L-arginine (Marletta, 1994; Moncada et al., 1991; Nathan & Xie, 1994; Schmitt & Walter, 1994) .
The similarity in molecular structure between the histamine H 2 -agonist, dimaprit (3-dimethylamino-propyl-isothiourea) and the endogenous NOS substrate L-arginine (Table 1) prompted us to study the eect of dimaprit and some dimaprit analogues on NOS activity. Dimaprit and some of its analogues were tested in vitro in a nNOS assay.
Methods

NOS activity
Male Wistar rats (Harlan CPB, 200 ± 220 g) were decapitated and the cerebellum was quickly removed. The isolated cerebellum was suspended in four times its weight of ice cold Tris/HCl-buer (50 mM, pH 7.4 at 48C), containing leupeptin (2 mM), phenylmethylsulphonal¯uoride 1 mM, dithiothreitol (1 mM), trypsin inhibitor from soybean (10 mg ml 71 ), aprotinin (2 mg ml 71 ), EDTA (0.1 mM), sucrose (320 mM), homogenized by pottering and ultra-sonic treatment (three times 10 s). After centrifugation of the homogenate (30 min at 48C with 100,0006g), the cytosolic fraction was obtained which was used in the experiments.
Forty ml of the cytosolic fraction was added to 60 ml of a 50 mM Tris/HCl buer (pH 7.4 at 378C), containing NADPH (1 mM), L-arginine (10 mM), CaCl 2 (2 mM), [ 3 H]-L-arginine (6 nCi) and the tested compound in a concentration range from 0.1 mM ± 0.1 mM. The reaction was carried out for 45 min at 378C, then terminated by adding 1 ml of ice-cold HEPES buer (20 mM, pH 5.5 at 48C) and putting the vials on ice. L-arginine was removed from the sample by adding 1 ml Dowex (Na + form, 200 ± 400 mesh, pH 7.0) to the mixture.
After shaking ®rmly, the separation was completed by centrifugation (15 min, 400 r.p.m. at 48C). The [3H]-L-citrulline was measured in 1 ml of the supernantant. Non-enzymatic conversion was determined by using heated tissue (1008C for 2 min). Inducible NOS activity was determined by using a calcium-free buer in the presence of EGTA (1 mM) (Bredt & Snyder, 1990) . The values found for non-enzymatic conversion and iNOS were subtracted from the total activity to yield speci®c nNOS activity, expressed in d.p.m. mg 71 . It should be noted that non-enzymatic conversion and iNOS activity were very low (51%) compared with nNOS activity. When inhibitors were used, activity was expressed as enzymatic conversion relative to no inhibitor (100%). The protein content was determined using the BioRad Assay (Bradford, 1976) .
Data analysis
The IC 50 values of the inhibitors were calculated using linear regression between the data points just above and just below the 50% activity. Calculations were performed using Excel software.
Drugs and materials
Dimaprit and dimaprit analogues used were synthesized according to Sterk et al. (1986) .
[
3 H]-L-arginine was obtained from Amersham (Slough, U.K.). All other chemicals used were of the highest purity grade commercially available.
Results
The histamine H 2 -agonist dimaprit and some of its analogues were tested for nNOS inhibitory activity using an in vitro assay which measures the conversion of
The NOS inhibitory activity of the compounds was ®rst established at a concentration of 100 mM. Compounds which inhibited NOS by less than 50% at this concentration were considered to be poor NOS inhibitors; for such compounds an IC 50 value of 4100 mM is listed. Compounds that caused enzyme inhibition greater than 50% at a concentration of 100 mM were tested further to determine the IC 50 value (Table 1) .
It was found that dimaprit and its analogues caused dosedependent inhibition of NOS (Figure 1) . The IC 50 of dimaprit is 49+14 mM. Shortening of the propyl chain of dimaprit to an ethyl chain (compound 1) improved the activity (IC 50 =23+5.4 mM). Addition of a nitro group or a methyl group (compounds 8 and 5) to the isothiourea moiety resulted in a reduction in inhibitory activity (IC 50 98+11 mM and 4100 mM respectively). Substitution of hydrogen atoms on both thiourea nitrogens in dimaprit (compound 6, two methyl groups and compound 9, one methyl and one cyanide group) also drastically reduced NOS inhibitory activity (IC 50 4100 mM for both compounds). The most active compound was aminopropylisothiourea (compound 2, IC 50 =4.1+0.9 mM) (Southan et al., 1996) while the butyl analogue of compound 2 (compound 3) had a higher IC 50 value (IC 50 4100 mM) than dimaprit.
The guanidine analogue of dimaprit (compound 10) appeared to be a poor NOS inhibitor (IC 50 4100 mM), while the nitro guanidine derivative (compound 11) had an IC 50 of 17+4.0 mM. However, nitrosylation of the isothiourea moiety of dimaprit (compound 8) resulted in an IC 50 of 98+11 mM, which was approximately twice that of dimaprit itself.
Discussion
In the present study we have shown that the histamine H 2 agonist dimaprit inhibits nNOS. Shortening of the propyl chain to an ethyl chain (compound 1) improves the nNOS inhibitory activity.
Removing the two methyl groups from the non-isothiourea nitrogen also improves the nNOS inhibition properties of the compound when the chain length is three carbons long (compound 2). For the four carbon long butyl analogue, demethylation of the nonisothiourea nitrogen (compound 3) resulted in loss of NOS activity. An explanation for the improved NOS inhibitory activity of the propyl compound (compound 2) might be the reported rearrangement to Figure 1 The concentration dependent inhibition of nNOS by the histamine H 2 -agonist dimaprit and aminopropylisothiourea (compound 2). The activity is expressed as conversion relative to no inhibitor (100%). Results show mean+s.e.mean, n=4.
mercaptoalkylguanidines (Southan et al., 1996) . This rearrangement requires a cyclic intermediate that opens to form a mercaptoalkylguanidine. The ring tension of the cyclic intermediate is for ®ve and six rings, derived from the ethyl or the propyl analogue respectively, much smaller than that of the seven ring formed from the butyl analogue. This means that the rearrangement to mercaptoalkylguanidines does not occur as readily for the butyl analogue compared to the ethyl or propyl analogue (Southan et al., 1996; Sterk et al., 1986) . If the mercaptoalkylguanidine is the active species, the dierence in ring tension in the cyclic intermediate explains the low activity of the demethylated butyl analogue on NOS inhibition ( Figure  2 ). Substitutions on either one or both of the isothiourea nitrogens reduce NOS inhibitory activity (compounds 5, 6, 7, 8 and 9) . Changing the isothiourea moiety of dimaprit into a guanidine moiety (compound 10) resulted in an enhanced IC 50 value. Nitrosylation of the isothiourea moiety (compound 8) rendered the resulting compound less active. This is consistent with the eect of substitution of a hydrogen atom by a methyl group on the isothiourea moiety of dimaprit (compound 5). However, an exception was found for the nitroguanidine compound (compound 11) which has greater nNOS inhibitory activity than the guanidine analogue (compound 10). Nitrosylation aects the pK a of the isothiourea and the guanidine moiety. Normally, these groups are protonated at physiological pH. Due to nitrosylation the groups are almost fully neutral at a pH of 7.4 (Sterk et al., 1984) . Surprisingly, nitrosylation had dierent eects on the nNOS-inhibition, i.e. increasing the activity of the guanidine analogue (compounds 10 vs 11) while reducing the activity of the isothiourea compound (dimaprit vs compound 8). Apparently the guanidine and the isothiourea compound interact dierently with nNOS (see also, Southan et al., 1995) .
The nNOS inhibition of dimaprit is observed in the same concentration range as that required for H 2 and H 3 receptor activation (Kohno et al., 1993) . To date, no direct coupling of histamine receptors and NOS enzymes has been reported. However, the present data suggest that functional agonism or antagonism may occur. For example, activation of H 2 receptors located in the uterus causes relaxation (Parsons et al., 1977) whilst inhibition of NOS will result in a counteracting eect (Papka et al., 1995) . Thus the mixed activity of dimaprit has to be taken into account in evaluating the pharmacological eects of this compound. Except for dimaprit itself, none of the tested analogues are active on the histamine H 2 -receptor (Sterk et al., 1984) . Clearly, some of the tested compounds do exhibit a nNOS inhibitory activity. Thus, the structure activity relation for the histamine H 2 -receptor and the rat nNOS is dierent, and it may be possible from this series of compounds to develop potent NOS inhibitors without H 2 receptor agonist activity.
